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Mycosis fungoides (MF) is a low-grade lymphoma of cluster of differentiation (CD)4þ , CD45ROþ , cutaneous
leukocyte antigen (CLA)+ T cells that homes to the skin. To understand the functional abnormalities in this
disease, we study the regulation of cytotoxic T-lymphocyte antigen (CTLA)-4 in peripheral blood mononuclear
cells (PBMCs) from patients with MF. CTLA-4 is a costimulatory molecule for T cells that functions in
immunoregulation. Unlike the expression of CD28, which is expressed constitutively on T cells, CTLA-4
expression is highly regulated. In the analysis of PBMCs in MF, we found that CTLA-4 is stimulated by phorbol
myristate acetate/A23187 to a greater level when compared to normals. This defect was seen in the dominant
clones of T cells. The increased CTLA-4 expression was significant between normal and MF, with a correlation
between higher expression of CTLA-4 and a higher grade of MF. In a patient whose disease progressed, the
CTLA-4 level increased. The abnormal level of CTLA-4 was confirmed at both the transcription and translation
levels. Although MF is associated with a Th2 bias, Th1 cytokines IL-2 and IFN-g enhanced CTLA-4 expression,
while IL-4 did not. These findings reveal an abnormal regulation of CTLA-4 expression in MF and show that
PBMCs from patients with MF have properties that are divergent from those of normal T cells.
Journal of Investigative Dermatology (2006) 126, 212–219. doi:10.1038/sj.jid.5700029
INTRODUCTION
Mycosis fungoides (MF) is a cutaneous T-cell lymphoma
(CTCL) that primarily affects the skin (Abel et al., 1993;
Berger and Edelson, 2003; Girardi et al., 2004; Kim et al.,
2005). This malignancy has an incidence in the population of
0.3–0.4 per 100,000, but the prevalence is higher due to the
low-grade chronicity of this disease. At the earliest stages of
the disease, clinically evident lesions manifest as patches
that, on histology, show few malignant T cells within the
epidermis. It is during the early stage where a clear diagnosis
of MF is difficult to confirm. However, as the disease
progresses, the burden of malignant T cells increases, leading
to greater distribution of clinical involvement in terms of
body surface involvement by T cells, such as tumors, and
extension into the circulation, resulting in Sezary syndrome.
The malignant cell shows surface markers of a skin-homing
memory T cell with cluster of differentiation (CD)4þ ,
CD45ROþ , cutaneous leukocyte antigen (CLA)þ pheno-
type.
There have been numerous molecular abnormalities
identified, including functional and genetic abnormalities
(Garatti et al., 1995). The loss of CD7, a marker on T cells,
can be useful for analysis of tissue by immunohistochemistry
(Ormsby et al., 2001). The high-affinity subunit of the IL-2
receptor is expressed often on the abnormal T cells, and this
has provided a target for biologic therapy, denileukin diftitox
(Saleh et al., 1998; Foss, 2004). However, there are few
abnormal biochemical findings so far that give an insight into
the pathogenesis of this disease. The association of MF with
HTLV-I has been reported previously (Hall et al., 1991), but
this association remains controversial (Bazarbachi et al.,
1997). There have been cytokine abnormalities identified
with early patch stage showing a Th1 bias, and Sezary disease
showing a Th2 bias (Saed et al., 1994; Lessin et al., 1995).
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a gene
initially identified in murine CD8þ T cells, but more recently
we have identified this gene in a screen for genes that are
increased in CD45ROþ , CD4þ , T cells (Warke et al.,
2001). CTLA-4 is a member of the costimulatory family of
molecules for T cells that plays an important role in
immunoregulation (Chambers et al., 1996; Thompson and
Allison, 1997; Oosterwegel et al., 1999; Chikuma and
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Bluestone, 2003). CTLA-4 binds B7 with high affinity and
competes with CD28. The function of CTLA-4 is to inhibit
T-cell activation and proliferation (Slavik et al., 1999). The
importance of CTLA-4 was revealed in transgenic studies
where the CTLA-4 gene was knocked out. Loss of CTLA-4
leads to profound proliferation of lymphocytes, leading to
death in the early postnatal period (Tivol et al., 1995). Unlike
the expression of the CD28 costimulatory molecule, which is
expressed on most T cells, CTLA-4 expression is low in
unstimulated cells and increases transiently upon stimulation.
The expression of CTLA-4 is highly restricted within T-cell
subsets of the immune system. The identification of CTLA-4
expression on CD4þCD25þ regulatory T cells provides a
new insight into the role of this gene product in T-cell
function and immunoregulation (Read et al., 2000; Sutmuller
et al., 2001). The finding of the CTLA-4 gene to be
preferentially expressed in the CD45ROþ , CD4þ T-cell
subset suggests that CTLA-4 plays an important role in the
secondary immune response. However, the precise function
of CTLA-4 in the human immune response is complex and
remains unclear.
The role of CTLA-4 in human disease is not known.
Polymorphisms that are associated with autoimmunity have
been discovered in the CTLA-4 gene (Ueda et al., 2003;
Barreto et al., 2004). The CTLA-4 polymorphisms have been
shown to be associated with an altered level of CTLA-4
expression (Ueda et al., 2003). CTLA-4 polymorphisms have
also been associated with atopy (Munthe-Kaas et al., 2004).
The role of CTLA-4 in malignant T-cell disease is unclear.
Recent studies have shown that T cells from patients with
cutaneous T-cell lymphoma can be induced into cells with a
Treg phenotype (Berger et al., 2005). To determine whether
regulation of CTLA-4 is abnormal in malignant T cells, we
studied CTLA-4 regulation in a disease of memory T cells,
MF. We describe the abnormal regulation of CTLA-4 in
freshly isolated peripheral blood mononuclear cells (PBMCs)
from patients with MF, a T-cell lymphoma of the skin. The
ability to rapidly express CTLA-4 in atypical T cells may
provide an explanation for the immunosuppression in
advanced MF.
RESULTS
Surface CTLA-4 increased in PBMCs from MF patients
CTLA-4 is a surface marker that is expressed on activated T
cells, CD45ROþ T cells, and Treg cells (Perkins et al., 1996;
Sutmuller et al., 2001; Warke et al., 2001). To determine the
regulation of CTLA-4 in freshly isolated cells from patients
with MF, PBMCs were stained for surface marker expression
with the appropriate conjugated antibodies and analyzed by
two-color flow cytometry. Table 1 provides a summary of the
clinical characteristics of the patients analyzed. In the
unstimulated state, there was minimal detectable CTLA-4
expression on T cells as determined by flow cytometry of
CD3þ cells from normal individuals and from patients with
MF. When PBMCs were stimulated with phorbol myristate
acetate (PMA) and the calcium ionophore A23187, there was
an increase in the level of CTLA-4 in CD3þ cells in PBMCs
from normals, with a range between 3 and 25% (Figure 1a).
Cells that were CD3 did not express significant levels of
CTLA-4. When PBMCs were analyzed in patients with MF,
there was a greater detectable increase in the expression of
CTLA-4 than normal individuals in CD3þ lymphocytes
(Figure 1a). The increase was most prominent in the CD3þ
subset. The range of expression of CTLA-4 in patients with MF
was from 15 to 70%. Confirmation of effective stimulation of
PBMCs was monitored by upregulation of CD69 on normal
and MF PBMCs, a surface marker that is rapidly upregulated
in activated T cells (Figure 1b). The expression of CTLA-4 in a
particular individual patient with extensive disease was
consistent temporally over multiple analyses (Figure 1c).
Clonal expression of CTLA-4
In patients with Sezary disease, there is a clonal proliferation
of malignant T cells in the peripheral circulation. To
determine whether the abnormal clone was responsible for
the predominant increased expression of CTLA-4, PBMCs
from a patient with a dominant clone as defined by a specific
TCR Vb epitope were analyzed. As shown by two-color flow
cytometry analysis, CTLA-4 expression was significantly
increased in the abnormal clone (Figure 2). Additional MF
patients, whose PBMCs expressed high levels of CTLA-4, had
an identifiable monoclonal population of T cells in the
peripheral blood, as determined by TCR gene rearrange-
ments. These findings support that CTLA-4 is expressed in the
abnormal T-cell clone.
CTLA-4 expression differs from normal individuals in early MF
and late MF
CTLA-4 is higher in patients with MF when compared to
normal individuals when analyzed by surface expression of
CTLA-4 (Figure 3a). To determine whether the expression of
CTLA-4 correlates with the extent of disease, patients with
skin-restricted disease, in early stages, were separated from
patients with extensive, late-stage disease. Early-stage
patients include those with patch, plaque, and tumors (IA–IIB
by the Bunn and Lamberg staging). Late-stage diseases are
those with Sezary disease and lymph node involvement
(III–IV). From an analysis of MF patients with early-stage and
late-stage diseases, it is observed that there is an increase in
the induced CTLA-4 expression in patients with more
Table 1. Summary of the clinical distribution of
patients
MF
staging TNMB
Number of
pts.
Average
age M/F
Atypical
cells
I T1–T2 14 57 9/5 Neg
II T1–T3
N1
3 76 2/1
III T4
N0–1
15 66.7 7/8 10/17
positive
IV T1–4
N0–3
2 63 0/2
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extensive disease (Figure 3b). Patients with worse disease
showed an increased level of CTLA-4 expression that was
statistically significantly different from that of normal
individuals (P¼0.002).
CTLA-4 mRNA increased in patients with MF
The regulation of CTLA-4 expression occurs at multiple
subcellular levels. It is known that CTLA-4 is regulated at the
level of transcription (Perkins et al., 1996). To determine
whether the increased CTLA-4 expression seen by flow
cytometry was correlated to the level of messenger RNA
expression, total RNA was isolated from PBMCs from normal
volunteers and from patients with MF. The level of CTLA-4
expression was determined by quantitative real-time PCR. In
the unstimulated state, the level of CTLA-4 was low;
however, it was elevated in the MF patients compared to
normal individuals. By 2 hours after stimulation, the level of
CTLA-4 can be measured by quantitative reverse transcriptase
(qRT)-PCR. The expression of CTLA-4 was higher among MF
samples from high-grade stages as well as low-grade stages in
comparison to the level of normal individuals at all time
points (Figure 4). The level of CTLA-4 expression was highest
in the patient group with the most severe disease (Table 2).
Total CTLA-4 protein expression in MF
CTLA-4 is a cell surface protein that plays a role in controlling
cell signaling. However, CTLA-4 exists in intracellular stores
that are rapidly upregulated to the cell surface upon
stimulation. To determine whether the total levels of CTLA-4
differ, immunoblotting for CTLA-4 was performed. PBMC
protein from two MF patients with Sezary disease, who have
high levels of CTLA-4 by flow cytometry, was compared to
PBMC protein from a normal individual. The level of CTLA-4
protein expressed was determined by immunoblotting using
an anti-CTLA-4 antibody and the protein level was normal-
ized to the expression of b-actin expression. There was an
increased level of CTLA-4 in unstimulated PBMCs from
Sezary patients when compared to the expression of CTLA-4
in normal patients, as shown by immunoblot (Figure 5a).
When the level of CTLA-4 was quantitated and normalized to
that of b-actin, the level of total CTLA-4 protein in
unstimulated PBMCs from MF was greater than 20-fold
higher than that of unstimulated normal PBMCs, and the
difference between the CTLA-4 level between PBMCs from
MF patients and normal was even greater after stimulation
(Figure 5b). The immunoblot findings support the increase in
CTLA-4 expression in PBMCs from MF patients, which was
determined by flow cytometry and RNA levels.
Expression of CTLA-4 increases as disease progresses temporally
The level of CTLA-4 expression correlates to the extent of
disease. To determine whether the level of CTLA-4 expres-
sion increases as the disease progresses, serial analysis of
CTLA-4 expression was carried out in a patient whose disease
advanced with increasing Sezary cells in the peripheral
blood. By analysis of the lymphocyte subset over time, there
was an increase in the level of CD4þCD45ROþ T cells in
the peripheral blood as the disease advanced from 50 to 95%
(Figure 6a). Flow cytometry analysis showed that the
distribution of T cells increased over time from a normal
distribution to that typically seen in Sezary syndrome, where
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Figure 1. Surface CTLA-4 expression in T cells determined by two-color flow
cytometry. PBMCs were stained with FITC-anti-CD3 for T cells and PE-anti-
CTLA-4. (a) CTLA-4 expression in PBMCs from a normal individual and an MF
patient after stimulation with PMA/A23187 for 18 hours. Results from a
representative analysis of a normal individual and an MF patient. The MF
patient has clinical stage IIIB with Sezary cells. In brief, the cells were stained
with FITC-anti-CD3 and PE-anti-CTLA-4 antibodies as described in Materials
and Methods. (b) Comparison of CD69 expression in normal and MF PBMCs
after stimulation, as measured by flow cytometry using FITC-anti-CD69. The
unstimulated cell population is represented by the solid line and the
stimulated cell population by the shaded region. (c) CTLA-4 expression
remains elevated over time. Two representative patients with atypical cells in
the blood with elevated CTLA-4 expression were analyzed at different times
several months apart. PBMCs were isolated and stained for CTLA-4 expression
by two-color flow cytometry as described in Materials and methods.
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Figure 2. Increased surface CTLA-4 expression in the dominant clone in MF.
PBMCs from a patient with clinical stage III with Sezary cells with a known
dominant TCR were stained with FITC-anti-TCR-Vb6 and PE-anti-CTLA-4.
The ability to express CTLA-4 was measured by two-color flow cytometry as
described in Materials and methods.
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CD4þ T cells constitute greater than 90% of lymphocytes.
Analysis of gene rearrangement in the peripheral blood
indicated the presence of a monoclonal population. When
the induced CTLA-4 level was examined by qRT-PCR from
sequential samples, there was a progressive increase in the
level of CTLA-4 expression over time, which correlated with
clinical progression (Figure 6b). The level of induced CTLA-4
expression was elevated compared to an earlier time even
after treatment with systemic chemotherapy. The increase in
the expression of CTLA-4 as the disease worsened shows a
direct correlation between disease severity and the ability to
express high levels of CTLA-4.
Cytokine regulation of CTLA-4 expression
The abnormal T cell in MF is thought to be derived from Th2T
cells (Vowels et al., 1994; Lessin et al., 1995). In late-stage
MF when tumor burden is high, there is an increased level of
IL-4. To determine whether increased CTLA-4 expression in
MF is from an increased level of cytokine, PBMCs were
preincubated in the presence of Th1 cytokines IL-2 and IFN-g,
and Th2 cytokine IL-4 for 4 days to measure the ability to
express CTLA-4. The preincubated cells were then stimulated
with PMA/A23187 and total RNA collected to determine the
expression of CTLA-4 by qRT-PCR. The measurement of
CTLA-4 was highest in cells preincubated with IL-2 and IFN-g
and lowest when cultured with IL-4 (Figure 7a). In normal
PBMCs, the highest level of CTLA-4 expression was seen in
cells cultured in conditions that favored a Th1 polarity. IL-4, a
Th2 cytokine, did not enhance CTLA-4 expression. The lack
of CTLA-4 induction by IL-4 is not from a defect in IL-4
signaling, as the level of IL-4 expression was highest in cells
treated with IL-4 (Figure 7b).
DISCUSSION
There are numerous molecular genetic defects described in
patients with MF (reviewed in Girardi et al., 2004; Kim et al.,
2005). Defects include chromosomal defects, oncogene
defects, surface marker expression abnormalities, and cyto-
kine expression defects (Kanavaros et al., 1994; Garatti et al.,
1995; Peris et al., 1999; Brender et al., 2001; Storz et al.,
2001; Gesk et al., 2003). Here we analyze peripheral T cells
from patients with MF and demonstrate that these cells have a
functional abnormality where CTLA-4 expression can be
stimulated to a higher level when compared to normal cells.
This is the first report describing the abnormal regulation
of CTLA-4 in freshly isolated lymphocytes from patients with
MF. From the PBMCs analyzed, the increased expression of
CTLA-4 was most prominent in patients with late-stage
disease, where abnormal cells are present in the blood, and
less pronounced in patients with early-stage disease, where
clinical involvement is restricted to the skin. The deregulated
expression of CTLA-4 did not seem to be affected by
treatment. In a patient with Sezary syndrome, photopheresis
did not alter the level of CTLA-4 expression, as the level of
CTLA-4 expression did not change significantly during
treatment (Figure 1c). Furthermore, the elevated expression
of CTLA-4 was found to be similar when measured at later
times for MF patients, indicating that the abnormality in
CTLA-4 expression in a patient is a stable defect that
may have diagnostic value. Significantly, the expression of
CTLA-4 was observed to increase in a patient whose disease
worsened (Figure 6).
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Figure 3. Comparison of induced CTLA-4 expression in normal volunteers
and patients with MF, as measured by flow cytometry of surface CTLA-4
expression. (a) Flow cytometry measurement of the percentage of cells that
expressed CTLA-4 in the CD3þ cells between normal (N¼21) and MF
(N¼27) (P¼ 0.002) individuals at 20 hours after stimulation. Normal¼ ,
and MF¼ . (b) Flow cytometry level of CTLA-4 expression, in percentage of
cells positive, was determined in patients with low- and high-grade disease in
comparison to normal. There was a significant difference between normal and
MF patients with low-grade disease, MF I–II (P¼ 0.004) and extensive disease,
MF III–IV (Po0.001); normal (N¼ 21), low-grade MF I–II (N¼ 21), high-grade
MF III–IV (N¼ 6). Normal¼ ; stage 1¼ ; stage II¼ ; stage III¼ ; stage
IV¼ x.
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Figure 4. CTLA-4 expression in PBMCs from patients with MF at the level of
mRNA. Quantitative PCR was performed using cDNA prepared from total
RNA isolated from PBMCs from normal individuals and from MF patients, as
described in Materials and Methods. Each graph represents the mean RNA
level plotted over time for one population ( ¼normal (N¼ 16), ’¼MF
III–IV (N¼3), m¼MF I–II (N¼ 12)). The RNA level is expressed as the fold
change relative to the mean of the normal unstimulated samples.
Table 2. Summary of CTLA-4 expression in MF
patients and normals
Normal MF I–II MF III–IV
CTLA-4 (avg% positive) 14 23 44
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The increased expression of CTLA-4 in MF PBMCs was
readily detectable at the mRNA level, as shown by real-time
PCR, and was also confirmed at the protein level in these
patients. The increase in the level of CTLA-4 at the RNA level
suggests that there is a transcriptional abnormality that
accounts for the enhanced expression in T cells in patients
with MF. Even in the unstimulated state from freshly isolated
cells, there was an increase in expression of CTLA-4 in the
MF PBMCs in comparison to normal PBMCs, as shown in
Figure 5. This was most evident in PBMCs from patients with
higher clinical grade disease. This underlying difference in
the expression of CTLA-4 suggests that the gene may be under
altered control or may be in a state that is readily accessible
by activating transcription factors to permit a higher level of
expression. The finding of increased CTLA-4 RNA expression
in patients with more severe disease is consistent with the
flow cytometry findings and supports that the increase in
CTLA-4 protein may be from altered transcription.
Since patients with MF, particularly the Sezary stage, have
a greater number of abnormal circulating CD45ROþ T cells,
the increased CTLA-4 in MF is consistent with the association
of increased CTLA-4 expression in CD45ROþ T cells (Warke
et al., 2001). Indeed, patients who had the highest level of
CTLA-4 expression were patients with Sezary syndrome, that
is, patients with the highest level of CD4þCD45ROþ T
cells in the peripheral blood (data not shown). Consistent
with the increased expression of CTLA-4 in the malignant T
cell, the level of CTLA-4 induction was higher in patients with
a higher clinical stage of MF, detected both by protein and
RNA levels. The highest level was seen in patients with
Sezary disease, where clonal tumor cells are present in the
peripheral circulation. The lower level of abnormal CTLA-4
in early disease is likely due to the abnormal T cell being
restricted to the skin, and a lower burden of the malignant T
cells.
The finding of increased CTLA-4 expression as the disease
worsens leads to two possibilities. One is that the abnormal
CTLA-4 expression is associated with the disease and is an
inherent defect of the abnormal memory T-cell itself. The
other possibility is that CTLA-4 expression is induced in T
cells as a consequence of the pathologic T cell. Given the
finding that patients with a dominant abnormal clone express
the highest level of CTLA-4 itself, the abnormal expression of
CTLA-4 is likely associated with the atypical malignant T cell.
More recently, the ability to induce CTLA-4 expression in
malignant T cells by coculture with dendritic cells supports
the abnormal expression of CTLA-4 in the MF T cell (Berger
et al., 2005). These cells upregulate Foxp3, a marker of Treg.
In fresh cells isolated from MF patients in this study, the level
of Foxp3 was not increased, which suggests that in the
absence of DC stimulation a Treg phenotype is not adopted.
Alternatively, it may reflect differences between freshly
isolated tumor cells and tumor cells cultured in vitro; thus,
additional studies will be necessary to determine Treg-like
properties of tumor-derived T cells.
CTLA-4 expression is not restricted to only MF T cells.
CTLA-4 has normal immune functions and its expression in
normal PBMCs can vary, as shown in Figure 3. Also, PBMCs
cultured in either Th1 or Th2 cytokines have differential
effects on CTLA-4 expression. Preincubation studies of
normal PBMCs under Th2 cytokines did not increase the
expression of CTLA-4, but rather Th1 cytokines enhance
CTLA-4 expression. This is in contrast to the findings in
murine clones, where CTLA-4 has been reported to be
expressed at a higher level in Th2-derived T-cell clones
(Alegre et al., 1998). Thus, regulation of CTLA-4 in human T
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Figure 5. Total CTLA-4 protein expression in PBMCs from MF patients. Two
patients with late-stage disease, MF1 and MF2, were analyzed. PBMCs were
isolated and stimulated. The cells were then lysed as described and 5 mg of
protein extract was separated by SDS-PAGE and transferred to polyvinylidene
difluoride membrane, as described in Materials and Methods. (a) Immunoblot
autoradiogram showing the expression of CTLA-4 and actin. Anti-CTLA-4 was
used to measure the level of CTLA-4 and anti-actin was used to monitor
loading and transfer efficiencies. (b) Quantitated level of CTLA-4 normalized
to actin level. The optical density of the autoradiogram was quantitated using
NIH ImageJ v1.33 software for CTLA-4 and actin, and the ratios were
calculated to determine the normalized expression of CTLA-4 in each sample.
The level of CTLA-4 for unstimulated normal PBMCs was set as 1.
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Figure 6. Level of CTLA-4 expression over time as MF disease progressed.
(a) Flow cytometry analyzing CD4 and CD45RO expression over 6 months.
The level of CD45RO T cells increased in a patient as the disease progressed.
Flow cytometry was performed as described in Materials and Methods. (b)
CTLA-4 expression as measured by qRT-PCR increased as disease progressed.
Total RNA was isolated from a patient whose disease progressed to Sezary
disease over months as indicated. Each vertical bar represents a time point
when the level of CTLA-4 expression at 4 hours after stimulation was
measured by qRT-PCR. The normalized level of CTLA-4 expression relative to
b2-microglobulin is represented. The bold arrow indicates when the patient
received chemotherapy.
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cells is complex and the increased CTLA-4 level observed in
MF patients with advanced disease is unlikely from the
increased level of IL-4 often seen in these patients.
CTLA-4 plays an important role in regulating the immune
response, although the exact function remains unclear and
the circumstances when CTLA-4 is expressed remain unclear.
We have found that CTLA-4 levels are higher in patients with
psoriasis than in normal volunteers, indicating that CTLA-4
levels may reflect immune activation. Since tumor immunity
is postulated to be present in early-stage MF (Kim et al.,
2005), the tumor immune response may contribute to the
increased level of CTLA-4 expression in PBMCs in a manner
seen in patients with psoriasis. Thus, the tumor in effect exerts
a trans-effect on the normal immune response to account for
the increased level of CTLA-4 seen in patients with early
disease who have low circulating levels of tumor T cells.
However, it is important to point out that the level of CTLA-4
expression in psoriasis does not reach the level seen in
patients with advanced MF. In advanced disease, the level of
CTLA-4 expression is primarily from the malignant clone
(Figure 2).
CTLA-4 is important in the secondary immune response
and an inability to express CTLA-4 in knockout mice leads to
lymphoproliferation and death (Tivol et al., 1995). This
suggests that CTLA-4 function is needed to control excessive
lymphoproliferation by downregulating positive signals to
permit the development of T cells that are no longer
activated, such as memory T cells that are important in the
subsequent immune response. One mechanism for the direct
control of T-cell growth by CTLA-4 is by binding to AP2 and
inhibiting activation of IL-2 expression through inhibiting the
transcription factors AP-1 and NF-kB (Zhang and Allison,
1997; Fraser et al., 1999). An explanation for the proliferation
of tumor cells in MF is that the CTLA-4 signaling pathway
may be abnormal and is no longer inhibitory to suppress
proliferation. This may be one mechanism of escape from the
normal immune regulation. Indeed, the frequent association
of an increase in the transcription factors such as JunD or NF-
kB suggests that CTLA-4 may not be able to deliver an
inhibitory signal in the tumor cells (Qin et al., 1999, 2001).
Additionally, the increased expression of CTLA-4 in the
atypical tumor MF cell may be one mechanism by which the
MF tumor cell suppresses the proliferation of normal T cells,
thereby inducing immunosuppression.
Expression of CTLA-4 is important in appropriate control
of the immune response. CTLA-4 polymorphisms have
recently been associated with autoimmune diseases, but
have not been associated with human malignancy. The
enhanced CTLA-4 expression in MF may signify that the
atypical cell has regulatory similarities to memory T cells and
may contribute to the immune imbalances in patients with
advanced disease. In summary, we described the abnormal
regulation of the CTLA-4 gene in PBMCs from patients with
MF. This report shows an association of CTLA-4 deregulation
with human lymphoid malignancy. The association of
increased CTLA-4 with MF may suggest targeting CTLA-4
for treatment in the future. Furthermore understanding the
mechanism for deregulated control of CTLA-4 expression in
MF T cells may provide an insight into the pathogenesis of
this malignancy.
MATERIALS AND METHODS
Patients
Patients were recruited from the Henry Ford Hospital Lymphoma
Clinic and from the Yale University Lymphoma Clinic. The
volunteers provided written informed consent for the research study
under approved Medical Ethics Committee (Institutional Review
Board) protocols that adhered to the Declaration of the Helsinki
Guidelines at the Henry Ford Hospital and at the Yale University
Hospital. The patients were assessed for disease extent based on the
modified Bunn and Lamberg stage. Patients with low-grade disease
correspond to disease extent in clinical stage I–II. Patients with
severe disease correspond to those with clinical stage III–IV
involvement. There were 36 normal volunteers and 34 patients with
MF who provided specimen for analysis.
Tissue culture
Peripheral blood was obtained by routine phlebotomy from patients
with MF, and normal PBMCs were purified from pheresis collars
from the American Red Cross under a research protocol approved by
the Henry Ford Hospital IRB. In brief, PBMCs were diluted with
Hank’s buffer, underlayered with Lymphoprep (Axis-Shield PoC,
Oslo, Norway) gradient and separated by centrifuge at 1,600 g for
30 minutes. The band of PBMCs was isolated by aspiration and
washed to remove the Lymphoprep. To remove residual red blood
cells, the PBMC pellet was incubated with ammonium chloride
potassium lysis buffer for 5 minutes. PBMCs were cultured in
RPMI media (Invitrogen Corporation, Carlsbad, CA) with 10%
bovine calf serum. Cells were stimulated with PMA at 25 ng/ml
and A23187 calcium ionophore at 0.1 mg/ml for 18 hours and stained
with the appropriate fluorescent antibody for analysis by flow
cytometry.
Antibodies
PBMCs were labeled with the following appropriate conjugated
antibodies, FITC, phycoerythrin (PE), and peridinin chlorophyll
protein, for detection by flow cytometry: peridinin chlorophyll
protein-anti-CD3, peridinin chlorophyll protein-anti-CD4, PE-anti-
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Figure 7. Cytokine regulation of CTLA-4 expression. (a) Level of CTLA-4
induced after preincubation with anti-CD3, IL-2, and IFN-g. PBMC from a
normal individual was preincubated in the presence of anti-CD3 (1 mg/ml), IL-
2 (10 U/ml), IFN-g (1,000 U/ml), or IL-4 (500 U/ml) for 4 days prior to
restimulation with PMA/A23187. CTLA-4 measured as described in Materials
and Methods. Results are representative of two independent experiments. (b)
IL-4 expression after coculture with anti-CD3 (1 mg/ml), IL-2 (10 U/ml), IFN-g
(1,000 U/ml), or IL-4 (500 U/ml) for 4 days prior to restimulation with PMA/
A23187. Total RNA was isolated and qRT-PCR was used to determine the
expression of IL-4 as described in Materials and Methods.
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CTLA-4, FITC-anti-CD45RA, FITC-anti-CD45RO, FITC-anti-VB6,
and FITC-anti-CD69 (BD Pharmingen, San Diego, CA). Controls
used were FITC-, PE-, or peridinin chlorophyll protein-IgG1/IgG2-
labeled antibodies. Flow cytometry was performed on a BD LSR flow
cytometer and analysis was performed using the Cell Quest software.
Anti-CD3 antibody muromonab-CD3 (OKT3) was purchased from
Ortho Biotech (Ranton, NJ).
Quantitative PCR analysis
Total RNA was isolated from PBMCs using TRIzol (Invitrogen
Corporation, Carlsbad, CA) as recommended by the manufacturer.
Reverse transcription was performed with total RNA to generate
cDNA, and quantitative PCR was performed using ABI7000 with the
machine set for 45 cycles, 951C for 15 seconds and 601C for
1 minute. Primers for analysis of CTLA-4 and b2-microglobulin have
similar amplification efficiencies. Analysis for relative gene expres-
sion was performed using the 2DDCT method (Livak and Schmittgen,
2001). The expression of CTLA-4 in each sample was performed in
duplicates and the level was normalized relative to b2-microglobu-
lin.
Immunoblot analysis
Total protein was prepared from 10 million cells by swelling and
lysing the cells for protein as described previously (Wong et al.,
1999). An equal amount of protein, 5 mg, was denatured in 2
Laemmli buffer and the proteins were separated by SDS-PAGE.
Separated proteins were transferred to a polyvinylidene difluoride
membrane in transfer buffer, washed in Tris-buffered saline, blocked
in blocking buffer and incubated for 1 hour with primary antibody,
followed by washing of the membrane. The primary antibody was
detected with the appropriate secondary antibody and the mem-
brane was incubated with developing solution for chemilumines-
cence (Supersignal, Pierce Biotechnology Inc., Rockford, IL),
followed by autoradiography to visualize the specific proteins.
Statistical analysis
The data are from at least duplicate experiments for flow cytometry
and qRT-PCR. Statistical significance was determined by the paired
Student’s t-test. Differences were considered significant when
Po0.05.
CONFLICT OF INTEREST
The author states no conflict of interest.
ACKNOWLEDGMENTS
We thank the American Red Cross Society of Detroit and Dermatology
support staff at the Henry Ford Hospital for assistance with patients. We thank
the Josephine Ford Cancer Center Flow Cytometry Core, Joe Media and Dr
Alex Nakeff for flow cytometer support. This work was in part supported by a
Clinical Career Development Award from the Dermatology Foundation, Fund
for Henry Ford Research, and KO8 AR-47818 from the NIH-NIAMS to HKW.
C.L.B. and R.L.E. received support from the New York Cardiac Foundation
and the NIH 5 P30AR 41942, and by the Yale Skin Disease Research Core
Center.
REFERENCES
Abel EA, Wood GS, Hoppe RT (1993) Mycosis fungoides: clinical and
histologic features, staging, evaluation, and approach to treatment. CA
Cancer J Clin 43:93–115
Alegre ML, Shiels H, Thompson CB, Gajewski TF (1998) Expression and
function of CTLA-4 in Th1 and Th2 cells. J Immunol 161:3347–56
Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C et al. (2004)
Evidence for CTLA4 as a susceptibility gene for systemic lupus
erythematosus. Eur J Hum Genet 12:620–6
Bazarbachi A, Soriano V, Pawson R, Vallejo A, Moudgil T, Matutes E et al.
(1997) Mycosis fungoides and Sezary syndrome are not associated
with HTLV-I infection: an international study. Br J Haematol 98:
927–33
Berger CL, Edelson RL (2003) Current concepts of the immunobiology and
immunotherapy of cutaneous T cell lymphoma: insights gained through
cross-talk between the clinic and the bench. Leuk Lymphoma
44:1697–703
Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N et al. (2005)
Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory
cells. Blood 105:1640–7
Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M et al.
(2001) STAT3-mediated constitutive expression of SOCS-3 in cutaneous
T-cell lymphoma. Blood 97:1056–62
Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S et al.
(1996) The role of CTLA-4 in the regulation and initiation of T-cell
responses. Immunol Rev 153:27–46
Chikuma S, Bluestone JA (2003) CTLA-4 and tolerance: the biochemical point
of view. Immunol Res 28:241–53
Foss F (2004) Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol
16:421–8
Fraser JH, Rincon M, McCoy KD, Le Gros G (1999) CTLA4 ligation attenuates
AP-1, NFAT and NF-kappaB activity in activated T cells. Eur J Immunol
29:838–44
Garatti SA, Roscetti E, Trecca D, Fracchiolla NS, Neri A, Berti E (1995) bcl-1,
bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas. Recent
Results Cancer Res 139:249–61
Gesk S, Martin-Subero JI, Harder L, Luhmann B, Schlegelberger B, Calasanz
MJ et al. (2003) Molecular cytogenetic detection of chromosomal
breakpoints in T-cell receptor gene loci. Leukemia 17:738–45
Girardi M, Heald PW, Wilson LD (2004) The pathogenesis of mycosis
fungoides. N Engl J Med 350:1978–88
Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Roupe G et al.
(1991) Deleted HTLV-I provirus in blood and cutaneous lesions of
patients with mycosis fungoides. Science 253:317–20
Kanavaros P, Ioannidou D, Tzardi M, Datseris G, Katsantonis J, Delidis G
et al. (1994) Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and
PCNA proteins and absence of association with Epstein–Barr virus.
Pathol Res Pract 190:767–74
Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al. (2005)
Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin
Invest 115:798–812
Lessin SR, Vowels BR, Rook AH (1995) Th2 cytokine profile in cutaneous
T-cell lymphoma. J Invest Dermatol 105:855–6
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(Delta Delta C(T)) method.
Methods 25:402–8
Munthe-Kaas MC, Carlsen KH, Helms PJ, Gerritsen J, Whyte M, Feijen M et al.
(2004) CTLA-4 polymorphisms in allergy and asthma and the TH1/TH2
paradigm. J Allergy Clin Immunol 114:280–7
Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB,
Sharpe AH (1999) CTLA-4 and T cell activation. Curr Opin Immunol
11:294–300
Ormsby A, Bergfeld WF, Tubbs RR, Hsi ED (2001) Evaluation of a new
paraffin-reactive CD7 T-cell deletion marker and a polymerase chain
reaction-based T-cell receptor gene rearrangement assay: implications
for diagnosis of mycosis fungoides in community clinical practice. J Am
Acad Dermatol 45:405–13
Peris K, Stanta G, Fargnoli MC, Bonin S, Felli A, Amantea A et al. (1999)
Reduced expression of CDKN2a/P16INK4a in mycosis fungoides. Arch
Dermatol Res 291:207–11
218 Journal of Investigative Dermatology (2006), Volume 126
HK Wong et al.
CTLA-4 Increased in Mycosis Fungoides
Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G et al. (1996)
Regulation of CTLA-4 expression during T cell activation. J Immunol
156:4154–9
Qin JZ, Dummer R, Burg G, Dobbeling U (1999) Constitutive and interleukin-
7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-
like proteins in cutaneous T-cell lymphoma cells. Blood 93:260–7
Qin JZ, Kamarashev J, Zhang CL, Dummer R, Burg G, Dobbeling U (2001)
Constitutive and interleukin-7- and interleukin-15-stimulated DNA
binding of STAT and novel factors in cutaneous T cell lymphoma cells.
J Invest Dermatol 117:583–9
Read S, Malmstrom V, Powrie F (2000) Cytotoxic T lymphocyte-associated
antigen 4 plays an essential role in the function of CD25(+)CD4(+) regu-
latory cells that control intestinal inflammation. J Exp Med 192:295–302
Saed G, Fivenson DP, Naidu Y, Nickoloff BJ (1994) Mycosis fungoides
exhibits a Th1-type cell-mediated cytokine profile whereas Sezary
syndrome expresses a Th2-type profile. J Invest Dermatol 103:29–33
Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G et al.
(1998) Antitumor activity of DAB389IL-2 fusion toxin in mycosis
fungoides. J Am Acad Dermatol 39:63–73
Slavik JM, Hutchcroft JE, Bierer BE (1999) CD28/CTLA-4 and CD80/CD86
families: signaling and function. Immunol Res 19:1–24
Storz M, Zepter K, Kamarashev J, Dummer R, Burg G, Haffner AC (2001)
Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma
(mycosis fungoides). Cancer Res 61:452–4
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN,
Wildenberg ME, Allison JP et al. (2001) Synergism of cytotoxic T
lymphocyte-associated antigen 4 blockade and depletion of CD25(+)
regulatory T cells in antitumor therapy reveals alternative pathways for
suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med
194:823–32
Thompson CB, Allison JP (1997) The emerging role of CTLA-4 as an immune
attenuator. Immunity 7:445–50
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH
(1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal
multiorgan tissue destruction, revealing a critical negative regulatory role
of CTLA-4. Immunity 3:541–7
Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al.
(2003) Association of the T-cell regulatory gene CTLA4 with suscept-
ibility to autoimmune disease. Nature 423:506–11
Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT et al. (1994)
Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J
Invest Dermatol 103:669–73
Warke VG, Krishnan S, Nambiar MP, Farber DL, Tsokos GC, Wong HK
(2001) Identification of differentially expressed genes in human
memory (CD45RO+) CD4+ T lymphocytes. Immunol Invest 30:
87–101
Wong HK, Kammer GM, Dennis G, Tsokos GC (1999) Abnormal NF-kappa B
activity in T lymphocytes from patients with systemic lupus erythema-
tosus is associated with decreased p65-RelA protein expression. J
Immunol 163:1682–9
Zhang Y, Allison JP (1997) Interaction of CTLA-4 with AP50, a clathrin-coated
pit adaptor protein. Proc Natl Acad Sci USA 94:9273–8
www.jidonline.org 219
HK Wong et al.
CTLA-4 Increased in Mycosis Fungoides
